Atacama CEO on Excella deal and development of PDG for HPAPIs

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmaceutical drug, Pharmacology

Atacama CEO on Excella deal and development of PDG for HPAPIs
CEO Steffen Mittwich updates in-PharmaTechnologist on Atacama Labs' pneumatic dry granulation (PDG) API processing tech, its deal with German CMO Excella and future development plans.

PDG, as Mittwich explained, is a granulation technology that uses lower compaction forces than standard methods and a special classifying unit to produce active pharmaceutical ingredient (API) particles that have improved “flow-ability” and maximum binding capacity.

He went on to say that the firm plans to develop versions of the PDG machine for the processing of high-potency APIs for the production of oncology drugs and others that require specialised handling procedures like antibiotics.

Mittwich also said that, while Atacama is happy to be working with 10 ten global contract manufacturing organisation (CMO) Excella​, the firm is to expanding worldwide accessibility to PDG through future deals.

Related news

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars